DSIP: Forty Years of Study, One Unresolved Riddle

The short version

DSIP — Delta Sleep-Inducing Peptide — is a nine-amino-acid peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) that was first isolated in 1977 from the cerebral venous blood of rabbits during electrically induced sleep. It was named for its ability to enhance slow-wave (delta) EEG activity when infused directly into the brain. That initial finding launched four decades of research, a lot of it promising, and yet as of the most thorough review of the field, the mechanism "remains a still unresolved riddle" ^[14].

Here is what the honest evidence picture looks like. DSIP has no identified receptor, no isolated gene, and no characterized precursor protein ^[14]. Its sleep-promotion evidence in native form is described by the same 2006 review as "extremely poorly documented and still weak" — with synthetic analogs, not the native peptide, driving clearest sleep effects. A small 1981 human trial did find improved sleep duration and fewer interruptions in six chronic insomniacs given intravenous DSIP ^[17], and more recent work in mice using a blood-brain-barrier-crossing fusion peptide showed large sleep improvements ^[13]. DSIP is sold only as a research chemical; it has never been approved or marketed as a drug by any regulator. This page reports what the studies show; it is not advice and lists no human dose.

What it is

DSIP is an endogenous linear nonapeptide with molecular formula C₃₅H₄₈N₁₀O₁₅. It occurs naturally in cerebrospinal fluid, blood and various tissues, including the hypothalamus. Its International Nonproprietary Name is emideltide, though no emideltide drug product has ever been approved or marketed by any regulator.

A naturally occurring phosphorylated form, DSIP-P, is described in the literature and reported as more potent in some assays. The peptide crosses the blood-brain barrier via a saturable transporter that is competitively inhibited by L-tryptophan — one of the few mechanistic facts that has held up across studies.

Outside controlled research settings, DSIP is available only as an unregulated research chemical with no pharmaceutical-grade quality, purity, dose-accuracy or sterility standard.

How it works

DSIP is the most mechanistically uncertain peptide on this desk. Despite four decades of research, no specific DSIP receptor, gene or precursor protein has been conclusively identified ^[14]. Its proposed roles encompass sleep regulation, HPA-axis (stress hormone) modulation, neuroendocrine secretion, and stress protection, but these are plausible inferences from pharmacological experiments rather than a resolved receptor-signaling model.

What is reasonably established:

• Blood-brain barrier transport. A saturable BBB transporter for DSIP has been demonstrated; it is competitively inhibited by L-tryptophan, suggesting the transporter may be shared with other amino-acid-like ligands.
• HPA-axis effects in humans. Intravenous DSIP at 25 nmol/kg in men significantly reduced plasma ACTH-like immunoreactivity for at least three hours, while cortisol followed its normal diurnal decline unchanged ^[16]. This is real human molecular data, but the mechanism connecting DSIP to ACTH suppression is not characterized.
• Growth hormone modulation in rodents. DSIP raised GH in rats via a dopaminergic relay (pimozide-sensitive); this effect did not replicate in human women in a later study, flagging a cross-species limit.
• Parabolic dose-response. Multiple studies have reported that DSIP's effects peak at intermediate doses with less effect at both lower and higher doses — a non-monotonic profile that complicates interpretation and protocol design.

A 2024 study using a BBB-crossing fusion peptide (DSIP-CBBBP) in PCPA-induced insomnia mice found the modified peptide reduced wakefulness by ~31%, restored melatonin, serotonin and dopamine levels, and increased hippocampal neuron density — outperforming unmodified DSIP ^[13]. This suggests the native peptide's limited BBB penetration may explain some of the inconsistency in earlier findings.

What the research shows

Critical review: sleep evidence is weak. A 2006 review in the Journal of Neurochemistry — the most authoritative synthesis of the DSIP literature — concluded that the link between DSIP and sleep has never been fully characterized, the sleep-promotion hypothesis is "extremely poorly documented and still weak," no DSIP gene, protein or receptor has been isolated, and that structural analogs rather than native DSIP drove the clearest sleep-promoting effects ^[14]. This is the baseline against which all other findings should be read.

Human sleep pilot. Acute intravenous synthetic DSIP at 25 nmol/kg improved disturbed sleep in six middle-aged chronic insomniacs: longer duration, fewer interruptions, slightly more REM sleep, and no daytime sedation ^[17]. Sleep-promoting effects appeared in the second hour after injection (the first hour showed slight arousal). This is the most direct positive human efficacy finding in the corpus, but the sample is six people and it has not been replicated in a modern controlled trial.

ACTH reduction in men. Intravenous DSIP at 25 nmol/kg produced a significant reduction in plasma ACTH-like immunoreactivity for at least three hours in men, while cortisol was unaffected ^[16]. This documents a real HPA-axis effect in humans at a defined dose; its meaning for sleep or stress is inferred, not established.

BBB-crossing fusion peptide in insomnia mice. A 2024 study engineered a DSIP fusion peptide (DSIP-CBBBP) to improve BBB penetration; it reduced average daily wakefulness from ~720 to ~500 minutes (~31%) in PCPA-induced insomnia mice, restored monoamine and melatonin levels, produced anxiolytic and antidepressant behavioral effects, and increased hippocampal neuron density — performing substantially better than unmodified DSIP ^[13]. This is promising preclinical evidence but is in an animal model using a modified peptide, not the native compound available as a research chemical.

Longevity and anti-tumor data in mice. Monthly courses of a DSIP-containing preparation (Deltaran) in female SHR mice extended maximum lifespan by 24.1%, extended survival of the last 10% of the cohort by 17.1%, reduced spontaneous tumor incidence 2.6-fold, and reduced bone-marrow chromosome aberrations by 22.6% ^[15]. These are large-magnitude effects from a single research group and require independent replication before strong claims can be made.

Reported effects, cautions & safety

Community-reported effects (anecdotal, not clinical evidence). DSIP's community profile is split between responders and non-responders. Among those who respond, the most commonly described benefits are: faster sleep onset and a smoother wind-down (mind quieting rather than sedative knockout), deeper-feeling more restorative sleep, and waking without heavy grogginess — a "no hangover" quality contrasted explicitly with melatonin or prescription sleep aids. Vivid dreams with stronger recall are a very commonly reported mixed effect (usually neutral or pleasant; occasionally disruptive). A large share of people report no noticeable effect at all; one practitioner estimate circulating in forums puts the non-response rate at roughly half. Headache is the most commonly cited adverse effect, generally mild and transient. Next-day grogginess and unpredictable timing — sedation arriving the following day rather than the target night — are also reported by a minority.

Cited safety cautions.

• Research-chemical supply only. No approved DSIP drug product exists. Material sold online is unregulated; purity, identity and sterility are not guaranteed ^[14].
• Mechanism unknown — interactions unpredictable. When no receptor is identified ^[14], there is no basis for predicting interactions with medications, supplements or pre-existing conditions.
• Essentially no long-term human safety data. Human study is limited to small early-1980s pilots; no large or long-duration controlled safety study has been conducted ^[17].
• Parabolic dose-response. Higher doses are not reliably more effective than intermediate ones, making informal dose escalation a poor strategy ^[14].
• Self-treating sleep with a research chemical can delay a real diagnosis. Persistent insomnia can reflect sleep apnea, a circadian disorder, depression or a thyroid problem. Using an unapproved peptide to chase better sleep delays evaluation.
• Combining with sedatives or alcohol is untested. DSIP has been studied in anesthesia-adjunct contexts and proposed to interact with the opioid system; stacking it with sedating substances has never been formally studied and could combine in unforeseeable ways.

Where it fits

Among the three peptides on this desk, DSIP is the most mechanistically opaque and the most narrowly evidenced in humans. It occupies a different niche from Semax and Selank: instead of cognitive enhancement or anxiety relief, its study target is sleep architecture — a distinct channel of the cognitive-health question. The recent BBB-crossing fusion-peptide work ^[13] suggests the research interest has not stalled, even if the native peptide's evidence base is thin. See the comparison page for a structured view of how all three line up.